CompareMarketResearchRequest a sample
Home / Healthcare / Radiopharmaceuticals

Healthcare · Market report

Radiopharmaceuticals Market Size, Share and Forecast 2026-2036

The global radiopharmaceuticals market is worth USD 12.1 bn in 2026 and is forecast to reach USD 39.3 bn by 2036, growing at a 12.5% CAGR. United States is the largest country market and Therapeutic is the largest by use segment.

USD 12.1 bnMarket size 2026
USD 39.3 bnForecast 2036
12.5%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global radiopharmaceuticals market is worth USD 12.1 bn in 2026 and is forecast to reach USD 39.3 bn by 2036, growing at a 12.5% CAGR. United States is the largest country market and Therapeutic is the largest by use segment.

ScopeRadioactive drugs used for diagnostic imaging (PET and SPECT tracers) and targeted therapy, including technetium-99m, fluorine-18 agents, lutetium-177 and radium-223 products.
IndustryHealthcare
Value 2025USD 10.8 bn
Value 2026USD 12.1 bn
Value 2036USD 39.3 bn
CAGR 2026-203612.5%
Volume 202651.3 million doses
Volume 2036158 million doses
Average price 2026USD 236 per dose
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Radiopharmaceuticals market size and forecast, 2026-2036

Exhibit 1The global radiopharmaceuticals market is forecast to grow from USD 12.1 bn in 2026 to USD 39.3 bn by 2036, more than triplingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 12.5%
Radiopharmaceuticals market value, 2025 to 2036Market value by year. 2025: USD 10.8 bn; 2026: USD 12.1 bn; 2027: USD 13.6 bn; 2028: USD 15.3 bn; 2029: USD 17.2 bn; 2030: USD 19.4 bn; 2031: USD 21.8 bn; 2032: USD 24.5 bn; 2033: USD 27.6 bn; 2034: USD 31.0 bn; 2035: USD 34.9 bn; 2036: USD 39.3 bn. Compound annual growth rate 2026 to 2036: 12.5%.202512.1 bn202621.8 bn203139.3 bn203612.5% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 12.1 bn
2027USD 13.6 bn
2028USD 15.3 bn
2029USD 17.2 bn
2030USD 19.4 bn
2031USD 21.8 bn
2032USD 24.5 bn
2033USD 27.6 bn
2034USD 31.0 bn
2035USD 34.9 bn
2036USD 39.3 bn

Radiopharmaceuticals market segmentation

By use

Exhibit 2Therapeutic is the largest segment by use, with 36.0% of 2026 revenueEstimated share of 2026 global revenue, by use
Radiopharmaceuticals market share by use, 2026Share of 2026 revenue by use. Therapeutic: 36.0%; Diagnostic PET: 34.0%; Diagnostic SPECT: 30.0%.Therapeutic36.0%Diagnostic PET34.0%Diagnostic SPECT30.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Diagnostic SPECT30.0%13.9%USD 3.6 bn4.2%
Diagnostic PET34.0%27.6%USD 4.1 bn10.2%
Therapeutic36.0%58.5%USD 4.4 bn18.1%

By isotope

Exhibit 3Lutetium-177 adds the most revenue by isotope, growing from USD 3.4 bn in 2026 to USD 20.4 bn by 2036Estimated revenue in USD by isotope, 2026 and 2036 forecast
Radiopharmaceuticals market by isotope, 2026 and 2036Revenue by isotope in 2026 and 2036. Lutetium-177: USD 3.4 bn in 2026, USD 20.4 bn in 2036, change +502%; Fluorine-18: USD 3.1 bn in 2026, USD 7.3 bn in 2036, change +132%; Other therapeutic and diagnostic: USD 1.7 bn in 2026, USD 4.7 bn in 2036, change +178%; Technetium-99m: USD 2.7 bn in 2026, USD 3.5 bn in 2036, change +32%; Gallium-68 and others PET: USD 1.2 bn in 2026, USD 3.4 bn in 2036, change +178%.20262036 forecastChangeLutetium-177+502%3.4 bn20.4 bnFluorine-18+132%3.1 bn7.3 bnOther therapeutic and diagnostic+178%1.7 bn4.7 bnTechnetium-99m+32%2.7 bn3.5 bnGallium-68 and others PET+178%1.2 bn3.4 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Technetium-99m22.0%9.0%USD 2.7 bn2.9%
Fluorine-1826.0%18.6%USD 3.1 bn8.8%
Gallium-68 and others PET10.0%8.6%USD 1.2 bn10.8%
Lutetium-17728.0%51.9%USD 3.4 bn19.7%
Other therapeutic and diagnostic14.0%12.0%USD 1.7 bn10.8%

By application

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Oncology62.0%75.8%USD 7.5 bn14.8%
Cardiology20.0%10.8%USD 2.4 bn5.8%
Neurology10.0%8.6%USD 1.2 bn10.8%
Other8.0%4.8%USD 968 mn6.8%

By source

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Reactor-produced34.0%28.0%USD 4.1 bn10.3%
Cyclotron-produced38.0%38.0%USD 4.6 bn12.5%
Generator-based14.0%14.0%USD 1.7 bn12.5%
Ac-225 and alpha emitters14.0%20.0%USD 1.7 bn16.6%

By delivery

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Injection78.0%80.0%USD 9.4 bn12.8%
Oral12.0%10.0%USD 1.5 bn10.5%
Inhalation and others10.0%10.0%USD 1.2 bn12.5%

Top 25 countries for radiopharmaceuticals by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 87.5% of 2026 revenue and the 25 countries below together hold 96.2%.

Exhibit 4United States is the largest country market at USD 5.3 bn in 2026, and the three largest countries hold 59.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Radiopharmaceuticals market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 5.3 bn, 44.0%; China: USD 968 mn, 8.0%; Germany: USD 847 mn, 7.0%; Japan: USD 847 mn, 7.0%; France: USD 605 mn, 5.0%; Italy: USD 484 mn, 4.0%; United Kingdom: USD 484 mn, 4.0%; Spain: USD 363 mn, 3.0%; South Korea: USD 363 mn, 3.0%; Australia: USD 302 mn, 2.5%.United States5.3 bn 44.0%China968 mn 8.0%Germany847 mn 7.0%Japan847 mn 7.0%France605 mn 5.0%Italy484 mn 4.0%United Kingdom484 mn 4.0%Spain363 mn 3.0%South Korea363 mn 3.0%Australia302 mn 2.5%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 5.3 bn44.0%USD 17.0 bn12.3%
2ChinaUSD 968 mn8.0%USD 4.8 bn17.4%
3GermanyUSD 847 mn7.0%USD 2.6 bn11.8%
4JapanUSD 847 mn7.0%USD 2.0 bn8.8%
5FranceUSD 605 mn5.0%USD 1.8 bn11.3%
6ItalyUSD 484 mn4.0%USD 1.3 bn10.7%
7United KingdomUSD 484 mn4.0%USD 1.5 bn12.2%
8SpainUSD 363 mn3.0%USD 1.1 bn11.7%
9South KoreaUSD 363 mn3.0%USD 1.2 bn12.5%
10AustraliaUSD 302 mn2.5%USD 903 mn11.6%
11CanadaUSD 236 mn1.9%USD 735 mn12.0%
12NetherlandsUSD 140 mn1.2%USD 436 mn12.0%
13SwitzerlandUSD 103 mn0.8%USD 322 mn12.1%
14BelgiumUSD 83 mn0.7%USD 259 mn12.0%
15MexicoUSD 70 mn0.6%USD 314 mn16.2%
16RussiaUSD 62 mn0.5%USD 192 mn12.1%
17AustriaUSD 54 mn0.5%USD 173 mn12.2%
18SwedenUSD 50 mn0.4%USD 153 mn11.9%
19IndiaUSD 45 mn0.4%USD 200 mn16.2%
20TaiwanUSD 42 mn0.3%USD 130 mn11.8%
21TurkeyUSD 39 mn0.3%USD 173 mn16.1%
22PolandUSD 36 mn0.3%USD 161 mn16.1%
23IsraelUSD 34 mn0.3%USD 153 mn16.3%
24DenmarkUSD 33 mn0.3%USD 102 mn12.1%
25ThailandUSD 31 mn0.3%USD 137 mn15.9%
Rest of worldUSD 454 mn3.8%USD 1.4 bn12.1%
Exhibit 5United States and China account for 57% of the USD 27.2 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Radiopharmaceuticals market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 12.1 bn. United States: +USD 11.7 bn; China: +USD 3.8 bn; Germany: +USD 1.7 bn; France: +USD 1.2 bn; Japan: +USD 1.1 bn; 20 other countries: +USD 6.6 bn; Rest of world: +USD 972 mn. Market value 2036: USD 39.3 bn.Market value 202612.1 bnUnited States+11.7 bnChina+3.8 bnGermany+1.7 bnFrance+1.2 bnJapan+1.1 bn20 other countries+6.6 bnRest of world+972 mnMarket value 203639.3 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Novartis
  • GE HealthCare
  • Lantheus
  • Curium
  • Bracco
  • Cardinal Health
  • Bayer

Group 2: Regional and specialist players

  • Jubilant Radiopharma
  • Eckert and Ziegler
  • Telix Pharmaceuticals
  • SOFIE
  • PETNET Solutions
  • ITM Isotope Technologies Munich
  • BWXT Medical
  • ANSTO
  • NTP Radioisotopes

Group 3: Emerging and niche players

  • Isotopia
  • Clarity Pharmaceuticals
  • NorthStar Medical Radioisotopes
  • Radiopharm Theranostics
  • Orano Med
  • Perspective Therapeutics

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the radiopharmaceuticals market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 12.5% is calculated from the resulting values.

The market is divided by use, by isotope, by application, by source, by delivery. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the radiopharmaceuticals market?

The global radiopharmaceuticals market is estimated at USD 10.8 bn in 2025 and USD 12.1 bn in 2026.

How fast will the radiopharmaceuticals market grow?

It is forecast to reach USD 39.3 bn by 2036, a compound annual growth rate of 12.5% from 2026, an increase of USD 27.2 bn.

Which country is the largest market for radiopharmaceuticals?

United States is the largest market by revenue at USD 5.3 bn in 2026, 44.0% of the global total. The three largest countries together hold 59.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 17.4% a year from 2026 to 2036.

Which radiopharmaceuticals segment is largest?

In the by use split, Therapeutic is the largest segment with 36.0% of 2026 revenue.

Who are the leading radiopharmaceuticals companies?

Global leaders include Novartis, GE HealthCare, Lantheus, Curium.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← RNA Therapeutics Radiotherapy →

All Healthcare markets →

Request a sample